These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

37 related articles for article (PubMed ID: 24704438)

  • 1. Hypothesizing the Green Synthesis of Tamoxifen Loaded Magnetic Nanoparticles for the Treatment of Breast Cancer.
    Tyagi N; Ralli T; Ali A; Kohli K
    Curr Mol Med; 2024; 24(5):537-546. PubMed ID: 37231732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral Efficacy of a Diselenide Compound Loaded in Nanostructured Lipid Carriers in a Murine Model of Visceral Leishmaniasis.
    Etxebeste-Mitxeltorena M; Moreno E; Carvalheiro M; Calvo A; Navarro-Blasco I; González-Peñas E; Álvarez-Galindo JI; Plano D; Irache JM; Almeida AJ; Sanmartín C; Espuelas S
    ACS Infect Dis; 2021 Dec; 7(12):3197-3209. PubMed ID: 34767359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydroxymethylnitrofurazone lymphatic uptake with nanostructured lipid carrier after oral administration in rats.
    Souza A; Scarim CB; Cotrim PC; Junior FB; Rocha BA; Calixto LA; Correia CJ; de Barros Araújo GL; Löbenberg R; Bou-Chacra NA; Breithaupt-Faloppa AC
    Nanomedicine (Lond); 2024 Feb; 19(4):293-301. PubMed ID: 38270378
    [No Abstract]   [Full Text] [Related]  

  • 4. Endosomal escape: a bottleneck in intracellular delivery.
    Shete HK; Prabhu RH; Patravale VB
    J Nanosci Nanotechnol; 2014 Jan; 14(1):460-74. PubMed ID: 24730275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physical characterization and bioavailability assessment of 5-fluorouracil-based nanostructured lipid carrier (NLC): In vitro drug release, Hemolysis, and permeability modulation.
    Mainuddin ; Kumar A; Ratnesh RK; Singh J; Dumoga S; Sharma N; Jindal A
    Med Oncol; 2024 Mar; 41(5):95. PubMed ID: 38526657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved Bioavailability of Poorly Soluble Drugs through Gastrointestinal Muco-Adhesion of Lipid Nanoparticles.
    Tan SLJ; Billa N
    Pharmaceutics; 2021 Oct; 13(11):. PubMed ID: 34834232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation, Characterization, and Anti-Cancer Activity of Nanostructured Lipid Carriers Containing Imatinib.
    Makeen HA; Mohan S; Al-Kasim MA; Sultan MH; Albarraq AA; Ahmed RA; Alhazmi HA; Alam MI
    Pharmaceutics; 2021 Jul; 13(7):. PubMed ID: 34371776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gefitinib loaded nanostructured lipid carriers: characterization, evaluation and anti-human colon cancer activity
    Makeen HA; Mohan S; Al-Kasim MA; Attafi IM; Ahmed RA; Syed NK; Sultan MH; Al-Bratty M; Alhazmi HA; Safhi MM; Ali R; Intakhab Alam M
    Drug Deliv; 2020 Dec; 27(1):622-631. PubMed ID: 32329374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Pharmacokinetics of a Lipid-Based Formulation of Risperidone, VAL401: Analysis of a Single Dose in an Open-Label Trial of Late-Stage Cancer Patients.
    Dilly SJ; Morris GS; Taylor PC; Parmentier F; Williams C; Afshar M
    Eur J Drug Metab Pharmacokinet; 2019 Aug; 44(4):557-565. PubMed ID: 30628010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor Microenvironment Targeted Nanotherapy.
    Fernandes C; Suares D; Yergeri MC
    Front Pharmacol; 2018; 9():1230. PubMed ID: 30429787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Catan-ionic hybrid lipidic nano-carriers for enhanced bioavailability and anti-tumor efficacy of chemodrugs.
    Liu B; He D; Wu J; Sun Q; Zhang M; Tan Q; Li Y; Zhang J
    Oncotarget; 2017 May; 8(19):30922-30932. PubMed ID: 28427235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel diindolylmethane derivatives based NLC formulations to improve the oral bioavailability and anticancer effects in triple negative breast cancer.
    Godugu C; Doddapaneni R; Safe SH; Singh M
    Eur J Pharm Biopharm; 2016 Nov; 108():168-179. PubMed ID: 27586082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long chain lipid based tamoxifen NLC. Part II: pharmacokinetic, biodistribution and in vitro anticancer efficacy studies.
    Shete H; Chatterjee S; De A; Patravale V
    Int J Pharm; 2013 Sep; 454(1):584-92. PubMed ID: 23535344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long chain lipid based tamoxifen NLC. Part I: preformulation studies, formulation development and physicochemical characterization.
    Shete H; Patravale V
    Int J Pharm; 2013 Sep; 454(1):573-83. PubMed ID: 23535345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha-lipoic acid-stearylamine conjugate-based solid lipid nanoparticles for tamoxifen delivery: formulation, optimization, in-vivo pharmacokinetic and hepatotoxicity study.
    Dhaundiyal A; Jena SK; Samal SK; Sonvane B; Chand M; Sangamwar AT
    J Pharm Pharmacol; 2016 Dec; 68(12):1535-1550. PubMed ID: 27709612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanostructured lipid (NLCs) carriers as a bioavailability enhancement tool for oral administration.
    Gaba B; Fazil M; Ali A; Baboota S; Sahni JK; Ali J
    Drug Deliv; 2015; 22(6):691-700. PubMed ID: 24670099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs.
    Dahan A; Hoffman A
    J Control Release; 2008 Jul; 129(1):1-10. PubMed ID: 18499294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tamoxifen nanostructured lipid carriers: enhanced in vivo antitumor efficacy with reduced adverse drug effects.
    Shete HK; Selkar N; Vanage GR; Patravale VB
    Int J Pharm; 2014 Jul; 468(1-2):1-14. PubMed ID: 24704438
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.